MedTrace Logo

Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

NCT07179042 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-29

No results posted yet for this study

Summary

The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.

Conditions

  • Intertrochanteric Femur Fracture
  • Muscle Atrophy

Interventions

DRUG

Placebo

Placebo tablets will be dispensed to the participants for 119-days.

DRUG

Metformin

Metformin tablets will be dispensed to the participants for 119-days.

Sponsors & Collaborators

Principal Investigators

  • Justin Haller, M.D. · University of Utah Orthopaedics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-04
Primary Completion
2030-09-30
Completion
2030-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07179042 on ClinicalTrials.gov